While I agree with the sentiment, I wonder who would replace him. With company value driven to such low levels, we'd have a hard time finding and paying someone who was qualified from a technical/science perspective. Furthermore, it would take several months for the new leader to get his feet on the ground and in that time, company value would likely decline further.
With a stock investment, it is best to take a short loss rather than hold on and capitulate when the stock has gone lower than you thought it ever might. So it is with top management; if you don't see a positive trend in the first year, it is time to move on. Berlin has been in the position for 3 years? The BOD has held on to him too long. (If you want an example of a board that cut it's losses check out the history of HPQ.)
Footnote: That would be 54 million pre-reverse-split shares.
I would add social media to that group. Economy is shifting from a focus on stuff to services. There is only so much stuff that you want to have in your house and garage.
What sort of infrastructure? Shipping ports or roads? With the high dollar, that isn't going to help exports. The only reason the dollar is high is because the Europeans are even worse at managing the economies and the Chinese control the value of their currency.
Will that be to go?
Yes, as you can see, I've brought my own bag.
Don't you think it is a poor reflection of the American economy to see stocks like CLF slide to new lows not on US economic results, but rather projections for the Chinese economy? Let's face it, without China to buy our raw materials and buy our gov't debt, we'd all be in lines hoping to trade in our old phones for a sandwich.
Look at the billing and revenue numbers for the last report. There is a huge gap. That's why they are making a special effort at collecting for the tests they have sold. When billing and revenue come close to lining up, you'll have a better sense of how many tests are being conducted and PAID for.
BTW - That gap also accounts for at least some of the negative gross margins they reported.
Well, look at that. All of a sudden the 18K at 3.62 ask are gone. Did someone buy them? I don't think so.
If the SEC had some insight, they'd put a small tax on any bid or sell offer. 0.25 cents per share would either generate lots of tax revenue or put a stop to this sort of manipulation.
Someone bought at the asking price of 3.62 a few minutes ago and sure enough, there are now 19K shares offered at that price. Clearly no one expects to sell all those shares; they are just there to discourage any enthusiasm for ROSG. OK, it's just my naive opinion.
We don't need no stinkin' materials. Just give us a tiny, shiny, box and lots of pretty colors and we are happy, happy, happy!
Really? When there are only 25K at the 6.15 bid. It would seem that if you really wanted to sell, a penny wouldn't hold you back.
I used to have faith in the market, but now it seems that people with faster access and more capital are in control. For those of you who trade often, it is a mistake to believe that you can win consistently. Its like Vegas; they want you to win once in a while so that you think positive and continue to put your money down.
10% drop since yesterday's open. 10% used to be a significant amount of cash, but these days it amounts to just 6 times Berlin's salary.
I hate ops expire days. Doesn't make much difference which stock you look at; if there is no news, the strike price with the most open contracts is a magnet.
The financial information was the same as the PR, but the discussion of the science showed some potential for the future. The biggest issue appears to be getting doctors to accept the ROSG tests as better replacements for existing cancer tests. The market is big enough, but it isn't as if doctors and patients are lining up, anticipating the next test. Furthermore there is competition, though this was not quantified.
Again, the science sounds promising and they continue to develop new tests (target is one per year.)
Partnerships were discussed at a high level, but the only $ amount I heard was the potential for a $75K milestone payment. As I suspected, there is confidentiality in the agreements or the milestone/royalty payments have not been negotiated.
Yeah - qtrly reports and updates in later 2015.
There are 11 sales reps for CUP tests. For thyroid test, they will add 2 reps. No projected sales per rep was given.
Gross billings and revenue as a % is improving. They are trying to set up more contractual payment arrangements (currently about 50-60% of total claims.)
FDA is going to get into regulating LDTs, but they do not see this as a hindrance to developing tests.
They talked about the Alzheimer's test, but I couldn't hear it (lawnmower running outside my window.)
Overall, a good call, but still a work in progress. If this was the first call after the IPO, I'd be much more enthusiastic.
Jake - why do you assume that any comment is based on a long or short position? If that is the case, we might as well ignore every comment since it is only self serving. If it makes you feel better, I'll simply post nothing but glowing comments about ROSG. Furthermore, I'll attack anyone who posts anything negative about this fantastically well managed, cutting edge powerhouse that is currently undervalued and could be a 10 bagger within a year.